Innocan Pharma Announces Second Quarter Fiscal year 2026 Results, With Revenue of US$5.25M (CAD 7.3M)

EarningsPositive

AI Analysis

Summary

Innocan Pharma reported second quarter fiscal year 2026 results with revenue of US$5.25M (CAD 7.3M) and a gross margin of 90.9%. The announcement demonstrates strong operational margins in the reported period.

Financial Highlights

Revenue

US$5.25M (CAD 7.3M)

Importance:2/10

Sentiment:

0.30

earningsQ2 2026revenuegross marginfinancial results

Related Companies

$INNP

Read the original article

Published by PR Newswire Pharma on August 31, 2026 8:01 PM

Read Original